Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor
June 27 2023 - 8:00AM
Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage
biotechnology company developing novel LAG-3 immunotherapies for
cancer and autoimmune disease, today announced the grant of a new
patent (number 11,684,654) entitled “Combined Preparations for the
Treatment of Cancer or Infection” by the United States Patent
Office.
This United States patent was filed as a second
divisional application and follows the grant of the United States
parent patent and first divisional patent announced in December
2020 and March 2021, respectively.
The claims of the new patent build on the
protection provided by the two previously granted patents, and are
directed to methods of treating cancer by administering Immutep‘s
lead active immunotherapy candidate eftilagimod alpha (“efti”) and
a PD-1 pathway inhibitor, specifically BMS-936559, durvalumab,
atezolizumab or avelumab. The expiry date of the patent is 15
November 2036 (including 312 days of patent term adjustment).
“We continue to build our patent estate around
lead candidate efti, which is a unique biomolecule and shows great
promise in being able to ultimately help diverse sets of cancer
patients, including those with more complex needs. Here we add
another key US patent which is closely aligned with our clinical
development pipeline. These key patents support ongoing investment
and allow us to confidently push forward across all of our business
functions, including clinical, manufacturing, and business
development,” said Marc Voigt, CEO of Immutep.
A continuation application and a further
divisional application have been filed to pursue other embodiments
of the invention.
About Eftilagimod
Alpha (Efti)
Efti is Immutep’s proprietary soluble LAG-3
clinical stage candidate that is a first-in-class antigen
presenting cell (APC) activator that stimulates both innate and
adaptive immunity for the treatment of cancer. Efti binds to and
activates antigen-presenting cells via MHC II molecules leading to
expansion and proliferation of CD8+ (cytotoxic) T cells, CD4+
(helper) T cells, dendritic cells, NK cells, and monocytes. It also
upregulates the expression of key biological molecules like IFN-ƴ
and CXCL10 that further boost the immune system’s ability to fight
cancer.
Efti is under evaluation for a variety of solid
tumours including non-small cell lung cancer (NSCLC), head and neck
squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its
favourable safety profile enables various combinations, including
with anti-PD-[L]1 immunotherapy and/or chemotherapy.
Efti has received Fast Track Designation in 1st
line HNSCC and in 1st line NSCLC from the United States Food and
Drug Administration (FDA).
About Immutep
Immutep is a clinical-stage biotechnology
company developing novel LAG-3 immunotherapy for cancer and
autoimmune disease. We are pioneers in the understanding and
advancement of therapeutics related to Lymphocyte Activation Gene-3
(LAG-3), and our diversified product portfolio harnesses its unique
ability to stimulate or suppress the immune response. Immutep is
dedicated to leveraging its expertise to bring innovative treatment
options to market for patients in need and to maximise value for
shareholders. For more information, please visit
www.immutep.com.
Australian
Investors/Media:Catherine Strong, Citadel-MAGNUS+61 (0)406
759 268; cstrong@citadelmagnus.com
U.S.
Investors/Media:Chris Basta, VP,
Investor Relations and Corporate Communications+1 (631) 318 4000;
chris.basta@immutep.com
Immutep (NASDAQ:IMMP)
Historical Stock Chart
From Apr 2024 to May 2024
Immutep (NASDAQ:IMMP)
Historical Stock Chart
From May 2023 to May 2024